Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD34+ and CD34- MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34+ MM cells.
Fukui-Morimoto A, Serizawa K, Fujimoto K, Hanamoto A, Iwata Y, Kakutani H, Kumode T, Hirase C, Morita Y, Tatsumi Y, Hanamoto H, Tanaka H, Matsumura I. Fukui-Morimoto A, et al. Among authors: hirase c. Int J Hematol. 2025 Jan;121(1):89-99. doi: 10.1007/s12185-024-03867-0. Epub 2024 Nov 12. Int J Hematol. 2025. PMID: 39531203 Free PMC article.
Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial.
Rai S, Inoue H, Hanamoto H, Matsuda M, Maeda Y, Wada Y, Haeno T, Watatani Y, Kumode T, Hirase C, Espinoza JL, Morita Y, Tanaka H, Tatsumi Y, Matsumura I. Rai S, et al. Among authors: hirase c. Int J Hematol. 2021 Aug;114(2):205-216. doi: 10.1007/s12185-021-03148-0. Epub 2021 Apr 17. Int J Hematol. 2021. PMID: 33864623
Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
Rai S, Inoue H, Sakai K, Hanamoto H, Matsuda M, Maeda Y, Haeno T, Watatani Y, Kumode T, Serizawa K, Taniguchi Y, Hirase C, Espinoza JL, Morita Y, Tanaka H, Ashida T, Tatsumi Y, Nishio K, Matsumura I. Rai S, et al. Among authors: hirase c. Cancer Sci. 2022 Feb;113(2):660-673. doi: 10.1111/cas.15224. Epub 2021 Dec 5. Cancer Sci. 2022. PMID: 34837284 Free PMC article.
Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators. Kizaki M, et al. Int J Hematol. 2019 Apr;109(4):426-439. doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb 14. Int J Hematol. 2019. PMID: 30762219 Clinical Trial.
Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma.
Haeno T, Rai S, Miyake Y, Inoue M, Fujimoto K, Fujii A, Iwata Y, Minamoto S, Taniguchi T, Kakutani H, Inoue H, Kumode T, Serizawa K, Taniguchi Y, Hirase C, Morita Y, Tanaka H, Tatsumi Y, Ashida T, Matsumura I. Haeno T, et al. Among authors: hirase c. J Clin Exp Hematop. 2023 Jun 28;63(2):99-107. doi: 10.3960/jslrt.23001. Epub 2023 Apr 28. J Clin Exp Hematop. 2023. PMID: 37121716 Free PMC article.
34 results